Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Takatsugu Ogata"'
Autor:
Yukiya Narita, Takatsugu Ogata, Yasunobu Ishizuka, Tomoki Sakakida, Munehiro Wakabayashi, Hiroyuki Kodama, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Masahiro Tajika, Kei Muro
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The combination of trifluridine/tipiracil hydrochloride (FTD/TPI) plus ramucirumab has demonstrated clinical activity in patients with advanced gastric cancer (AGC). We evaluated the efficacy and safety of this combination compared with thos
Externí odkaz:
https://doaj.org/article/4d7761430fc7499a8389396db24e579c
Autor:
Yasushi Kojima, Emi Mishiro-Sato, Teruaki Fujishita, Kiyotoshi Satoh, Rie Kajino-Sakamoto, Isao Oze, Kazuki Nozawa, Yukiya Narita, Takatsugu Ogata, Keitaro Matsuo, Kei Muro, Makoto Mark Taketo, Tomoyoshi Soga, Masahiro Aoki
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-23 (2023)
Abstract Cancer cachexia is a complex metabolic disorder accounting for ~20% of cancer-related deaths, yet its metabolic landscape remains unexplored. Here, we report a decrease in B vitamin-related liver enzymes as a hallmark of systemic metabolic c
Externí odkaz:
https://doaj.org/article/1ee9040a74a0436c807b06119e134c56
Autor:
Takatsugu Ogata, Yukiya Narita, Isao Oze, Ryosuke Kumanishi, Taiko Nakazawa, Yuki Matsubara, Hiroyuki Kodama, Akinobu Nakata, Kazunori Honda, Toshiki Masuishi, Hideaki Bando, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Seiji Ito, Masahiro Tajika, Kei Muro
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Recent trials have reported a median overall survival (OS) of 11–17 months in patients with advanced gastric cancer (AGC). However, it is unclear how recently approved drugs contribute to patient prognosis. Objectives: We aimed to evalu
Externí odkaz:
https://doaj.org/article/a824ca2e54864b8bb4822bd52882a5d0
Publikováno v:
Clinical Case Reports, Vol 9, Iss 1, Pp 50-56 (2021)
Abstract Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for poor general conditions in the case of MSI‐H tumor.
Externí odkaz:
https://doaj.org/article/ec1a9c9e16674bda97b64011d9c0c8f2
Autor:
Misato Ogata, Masahito Kotaka, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Takeshi Kato, Akihito Tsuji, Hironaga Satake
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234314 (2020)
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients
Externí odkaz:
https://doaj.org/article/e1f1577bf5554925bebe0578946c2bc5
Autor:
Takatsugu Ogata, Yuichiro Kikawa, Misato Ogata, Hironaga Satake, Yukimasa Hatachi, Hisateru Yasui
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 699-704 (2018)
Diffuse liver metastasis is a rare pattern of liver metastasis that is associated with hepatic failure and poor prognosis. We experienced 2 cases of acute liver failure due to diffuse metastasis that could not be detected using computed tomography. I
Externí odkaz:
https://doaj.org/article/7f1f0291ea2b46b4a95872c05b476c6c
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 1, Pp 143-150 (2018)
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with
Externí odkaz:
https://doaj.org/article/f16fae0507314f1794afa38fc77645ca
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 3, Pp 885-889 (2017)
Oxaliplatin-based chemotherapy is widely used to treat advanced cancer. Oxaliplatin-induced hyperammonemic encephalopathy is rarely reported. Here, we report a case of oxaliplatin-induced hyperammonemic encephalopathy occurring after gemcitabine plus
Externí odkaz:
https://doaj.org/article/da80f94a099b40e2bb1810c4ec42f701
Autor:
Takatsugu Ogata1, Yukiya Narita1, Wainberg, Zev A.2, Van Cutsem, Eric3, Kensei Yamaguchi4, Yongzhe Piao5, Yumin Zhao6, Peterson, Patrick M.6, Wijayawardana, Sameera R.6, Paolo Abada6, Anindya Chatterjee6, Kei Muro1 kmuro@aichi-cc.jp
Publikováno v:
Journal of Gastric Cancer. Apr2023, Vol. 23 Issue 2, p289-302. 14p.
Autor:
Ryosuke Kumanishi, Shigenori Kadowaki, Seiichiro Mitani, Tomohiro Matsushima, Takatsugu Ogata, Yukiya Narita, Toshiki Masuishi, Hideaki Bando, Masahiro Tajika, Hisateru Yasui, Hiroki Hara, Kei Muro
Publikováno v:
International Journal of Clinical Oncology. 28:756-763
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::827594ba3b52310613a37e805cb4a5fc
https://doi.org/10.1007/s10147-023-02330-0
https://doi.org/10.1007/s10147-023-02330-0